ArticleCell communication and signaling : CCS2025
miR-125b-5p and miR-145a-5p modulation drives functional enhancement of Wharton's Jelly-MSCs derived small extracellular vesicles in response to hypoxia preconditioning.
Article in Cell communication and signaling : CCS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRegenerative medicine therapies offer hope for conditions previously limited to supportive care. The COVID-19 pandemic underscored the urgent need for treatments targeting systemic inflammation. Mesenchymal stem cells (MSCs) are widely recognized for their regenerative and immunomodulatory properties. Recent research shows that hypoxic priming enhances MSCs' therapeutic potential, particularly by increasing the release and modifying the cargo of their extracellular vesicles (EVs). These EVs imitate many of the regenerative and immunomodulatory effects of MSCs, making them a promising cell-free therapeutic option. This study aimed to compare the regenerative and immunomodulatory capacities of small EVs (sEV; less than 200 nm) derived from bone marrow (BM) and wharton's jelly (WJ) MSCs, cultured under normoxic and hypoxic conditions, and decipher their underlying functional mechanisms.
methodsBM and WJ-MSCs were isolated and expanded. Hypoxia exposure was provided at 1% oxygen concentration for 24 h. sEV were isolated using ultracentrifugation, and in vitro functional assessments were performed using skin specific human sourced cell lines for fibroblasts, keratinocytes and macrophages. miRNA modulations were performed via transfection technique and mechanism of action of sEV were determined. Additionally, in vivo analysis was performed in a traumatic wound rat model, and molecular pathway analysis was performed in animal wound tissues.
resultsThrough comprehensive in vitro and in vivo evaluations, this study aimed to identify the most potent candidate for regenerative medicine while elucidating the underlying molecular mechanisms. By analysing sEV cargo and the associated molecular pathways within a traumatic wound model, the study revealed that WJ-MSCs exhibit superior regenerative potential. Furthermore, it demonstrated that hypoxia priming enhances their therapeutic efficacy through the involvement of miR-125b-5p and miR-145a-5p, which drive immunomodulation and regeneration by targeting IL-6R/NFκB axis and TGF-β2/SMAD4 pathway, respectively. These findings underscore the significance of WJ-sEV as a promising avenue for personalized regenerative therapies, positioning miR-125b-5p and miR-145a-5p as key therapeutic targets for bioengineering of sEVs.
conclusionBy exploring these comparative functions, the study provides insights into the optimization of sEV-based therapies as a cutting-edge approach in regenerative medicine, and reflects the suitability of WJ-sEV as an ideal acellular therapeutics' candidate for translational regenerative and immunomodulatory applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.